Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"
Manager TitleAgeSince
Chief Executive Officer 53 30/08/2022
Director of Finance/CFO 55 02/05/2023
Chief Tech/Sci/R&D Officer 51 -
Director TitleAgeSince
Chairman 71 15/04/2021
Director/Board Member 63 15/04/2021
Director/Board Member 68 15/04/2021
Change 5-day change 1-year change 3-year change Capi.($)
+5.88%+8.00% - - 1.51M
-0.34%-0.08%-12.15%-10.46% 43.44B
+2.24%+8.17%+304.26%+528.58% 33.54B
-2.38%-7.79%+7.98%-22.32% 28.48B
+2.32%+3.69%+6.76%+40.87% 29.2B
-0.57%+3.77%+12.66%+20.42% 25.34B
+0.34%+7.46% - - 14.36B
+0.26%-3.49%+51.47%+103.50% 13.05B
+0.54%-2.27%+3.93%+4.80% 12.67B
-0.09%+0.93%+101.31%+81.41% 12.28B
Average +0.83%+0.80%+59.53%+93.35% 23.6B
Weighted average by Cap. +0.29%+0.79%+62.57%+104.85%
Logo Amniotics AB
Amniotics AB (publ) is a Sweden-based biotech company that develops cell therapy drugs based on mesenchymal stem cells from amniotic fluid in its in-house GMP licensed facility. Amniotics' own marker technology is used to identify and select stem cells for different tissue types; Lung (PulmoStem), Brain (CogniStem), Kidney (NephroStem), Skin (CutiStem). It allows for selecting the type of cell to be used for specific tissue. The company has developed a process - patented in all steps - which includes collection of amniotic fluid, with a medical device developed by Amniotics, followed by sorting and propagation of stem cells and packaging of product in ampoules in its own GMP facility. Amniotics is a technology and service provider to Universities, Hospitals, and the Biopharmaceutical industry.
Employees
4
  1. Stock Market
  2. Stocks
  3. AMNI Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!